Industry landscapes
The companies, capital and talent shaping healthtech in Australia. Find the leaders. Understand the segments. See where the activity is.
An industry ecosystem,
measured in context.
24 featured companies from the funding, hiring, revenue and team-size leaderboards.
Locked revenue figures are available in Radar; the eight company financial previews stay the same throughout this page. A dash means the figure is outside these featured lists. Revenue years vary by company; the figures are not a like-for-like revenue comparison. Compare annual accounts ↗
Recently founded means a recorded 2023–2026 founding year and no recorded parent, acquirer or public-company status. These companies are not labelled startups without that separate classification.
Explore classified startups in Radar ↗A few useful ratios bring the size of this ecosystem into perspective.
73 of 2,017 tracked companies have open roles.
217 of 2,017 tracked companies have a recorded round.
Share of disclosed capital received by the three largest recorded recipients.
Midpoint of 291 rounds with a disclosed amount.
Scale is concentrated. Opportunity is broader. The three largest funding recipients hold 23.4% of disclosed capital, while 89.2% of tracked companies have no recorded funding round.
Explore the segments →Recorded company formation and disclosed funding across the complete annual series shown.
Sum of recorded funding rounds · USD
| Year | Funding (USD) | Founded | Raising |
|---|---|---|---|
| 2016 | $118.86M | 108 | 19 |
| 2017 | $127.62M | 128 | 20 |
| 2018 | $42.62M | 143 | 14 |
| 2019 | $122.63M | 154 | 28 |
| 2020 | $179.88M | 156 | 30 |
| 2021 | $684.86M | 98 | 37 |
| 2022 | $281.39M | 62 | 33 |
| 2023 | $174.99M | 70 | 25 |
| 2024 | $70.52M | 42 | 17 |
| 2025 | $377.01M | 8 | 23 |
Share of all disclosed company funding.
365 recorded rounds since 2016
Recorded participation in healthtech company rounds since 2016.
Backed by .
Backed by .
Backed by Aviron Investment Management and Brandon Capital and others.
Backed by Gobi Partners and Horizons Ventures.
Backed by Spectrum Equity and Athletic Ventures.
Backed by .
Backed by .
Backed by .
Backed by National Reconstruction Fund and Aware Super and others.
Backed by General Atlantic.
Backed by Horizons Ventures and Sonic Healthcare and others.
Backed by Point72 Ventures and Blackbird Ventures and others.
Backed by Bond Capital and Blackbird Ventures and others.
Backed by SGH and Cochlear and others.
Backed by Spectrum Equity and Athletic Ventures.
Backed by SPRIM Global Investments and LGT Crestone and others.
Backed by Inspire Impact.
Backed by Gina Rinehart and Gretel Packer and others.
The measured Australia identity-to-filing probe did not produce a qualifying designated legal or national-ID join: bare ticker overlaps lack a recorded ASX exchange designation and are not designated legal or national identifiers.
How the Australia companies on this page show up online: the sites people visit, the apps they install, and how often those apps ship.
28 of the 2,017 companies on this page carry a measured traffic record (1.4%); these are the largest of those, by monthly visits. The median among them is 340,551 visits.
| Company | Monthly visits | Authority | Mobile |
|---|---|---|---|
| Chemist Warehousechemistwarehouse.com.au | 18,854,540 | 79 | 80.3% |
| HotDochotdoc.com.au | 8,552,236 | 62 | 89.3% |
| eRx Script Exchangeerx.com.au | 5,798,568 | 31 | 98.9% |
| Clinikocliniko.com | 4,788,990 | 46 | 67% |
| Healthenginehealthengine.com.au | 1,867,825 | 60 | 79.1% |
| Zandazandahealth.com | 1,508,257 | 44 | 47.5% |
| fatsecretfatsecret.com | 1,489,699 | 67 | 53.3% |
| AutoMed Systemsautomedsystems.com.au | 1,435,767 | 34 | 87.3% |
| Halaxyhalaxy.com | 1,255,619 | 42 | 30.3% |
| PracSuitepracsuite.com | 608,704 | 36 | 57.2% |
Visits and authority are third-party web estimates, not company-reported figures.
269 of these companies (13.3%) publish at least one Android app — 506 apps in all, carrying 83.3M installs between them.
| App | Installs | Rating | Store category |
|---|---|---|---|
| Calorie Counter by fatsecretfatsecret | 62.8M | 4.5 | Health & Fitness |
| HotDocHotDoc | 3.9M | 4.1 | Medical |
| Feed Baby - Baby TrackerFeed Baby | 2.3M | 4.3 | Parenting |
| Sleeptot - Baby White NoiseSleeptot | 2.3M | 4.1 | Parenting |
| HealthengineHealthengine | 1.9M | 4.3 | Medical |
| Smiling Mind: Mental WellbeingSmiling Mind | 1.7M | 4.2 | Health & Fitness |
| Brainbuddy: Quit Porn ForeverBrainbuddy | 797.5K | 4.7 | Health & Fitness |
| The Chemist Warehouse AppChemist Warehouse | 646K | — | Medical |
| Medadvisor Medication TrackerMedAdvisor | 513K | 3 | Medical |
| Connect PatientZed (Other Healthcare Technology Systems) | 357.3K | — | Medical |
Installs are lifetime totals to date at the June 2026 store reading — a measure of reach, not of people using an app today.
The busiest app inside each of this page’s own segments, with the quarterly release trend behind it (2024Q1–2026Q2).
| Segment | Apps | Installs | Leading app | Release trend |
|---|---|---|---|---|
| Disease Self Management | 115 | 72.2M | Calorie Counter by fatsecret 62.8M | |
| Fitness & Wellness Tech | 12 | 64.7M | Smiling Mind: Mental Wellbeing 1.7M | |
| Healthcare Booking Platforms | 94 | 9M | HotDoc 3.9M | |
| Healthcare It | 336 | 6.5M | Connect Patient 357.3K | |
| Mom & Baby Care | 7 | 2.4M | Feed Baby - Baby Tracker 2.3M | |
| Online Mom & Baby Care | 2 | 2.3M | Sleeptot - Baby White Noise 2.3M | |
| Clinical Labs It | 60 | 572K | Scanaptics Patient 50.6K | |
| Clinical Data Repository | 56 | 549.7K | SynRad Patient Portal 31.8K |
A company can carry several segment tags, so these rows overlap and should not be added together. Trend lines are zero-based and share one quarter grid, so a flat line is a quiet segment, not a missing one.
New apps published, beside apps whose most recent update landed in that quarter — the second bar is how much of the shelf is still being maintained.
Darker bars are new releases, lighter bars apps updated. 343 of 506 apps carry a release date. The series ends at 2026Q1, the last quarter that closed before the June 2026 reading.
Explore the segments behind the headline numbers.
Rank segments by scale, hiring or disclosed funding.
Companies can sit in several segments. Counts and funding overlap.
The largest measured segment in this report snapshot.
45 companies hiring · $2.01B disclosed funding
Explore in RadarCommon revenue models; a company can use more than one.
Recorded corporate activity linked to companies in this landscape.
Radoff and Torok, who with certain of their affiliates comprise the Radoff-JEC Group, are now offering $2.35 per share plus a contingent value right.
QuidelOrtho said this week that it has completed the acquisition of UK-based Lex Diagnostics for about $100 million in cash.
BlinkLab (ASX: BB1) has conducted an oversubscribed A$17.5 million placement at A$0.65 per share to fund trials for its autism diagnostic aid (Dx1) and advance US ADHD clinical studies.
Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX) launches an offering of US$550 million convertible notes due 2031 to be issued by its wholly‑owned subsidiary, Telix Pharmaceuticals (Investments) Inc. (the "Issuer"), and guaranteed by Telix and Telix Pharmaceuticals (US) Inc.
Omniscient, the Paris‑based decision intelligence platform built for boards and senior executives, has raised $4.1 million in a pre‑seed round led by Seedcamp, with participation from Plug and Play, MS&AD, Raise, and Bpifrance, to replace the 150+ fragmented intelligence tools that large organisations currently manage.
Atomo Diagnostics (ASX:AT1) is also raising up to $1m through a share purchase plan offering eligible shareholders the opportunity to apply for up to $30,000 worth of shares.
US-based drone logistics company Zipline has raised an additional $200 million, bringing its recent Series H funding round to $800 million.
Cortical Labs , a Melbourne-based deep tech company developing biological computing systems, secured an undisclosed investment in a round co-led by Horizon Ventures and 3C.
Healthcare technology also featured among the recipients, with Eyeonic receiving $250,000 to enhance its artificial intelligence-powered glaucoma testing system designed for use outside traditional clinical settings.
The acquisition’s completion is set to complete in the middle of this year pending customary regulatory approvals.
Top 10 categories among 370 recorded events in the 24-month window.
8 companies with recorded IPO activity
IPO · ASX3 reports
IPO1 reports
IPO1 reports
IPO · Australian Securities Exchange5 reports
IPO · ASX1 reports
IPO · ASX1 reports
IPO · ASX1 reports
IPO · Nasdaq Global Market3 reports
17 tracked people moves
Appointment Non-Executive Director
Appointment Non-Executive Director
Appointment Chair of its board
Appointment Non-Executive Director
Appointment Chief Product Officer
Retirement
Appointment Chief Executive Officer and Managing Director
Appointment Company Secretary and General Counsel
Products, platforms and features in the recorded window
Delivery
20 recorded customer wins
Customer: regeneron pharmaceuticalsBiopharmaceutical
Customer: Advance Realty Investors and Greek Real Estate Partners (GREP)Logistics
Customer: northeast georgia health systemHealthcare
Customer: University Hospital HeidelbergHealthcare IT
Customer: Advanced Radiology ManagementHealthcare IT
Customer: OncolifeHealthcare Technology
14 recorded events
approved for saleU.S.
application accepted for approvalNational Health Authority (NMPA)
approval for investmentChina ODI
approved for saleCE Mark
6 tracked suits
breach of fiduciary duties over tax benefit planCivil · Ongoing
Federal Securities Laws violationCivil · Filed
Reported company results in the recorded window.
Median across 66 reported growth observations; companies may contribute multiple periods.
Company-linked deal reports; status is preserved as recorded.
| Acquirer → target | Status | Date | Value / context |
|---|---|---|---|
| Radoff-JEC Group→Seer ↗ | Announced | 2026-04-24 | Not stated in snapshot |
| quidelortho→Lexdiagnostics ↗ | Completed | 2026-04-24 | $100.0M |
| hims & hers→Eucalyptus ↗ | Announced | 2026-03-24 | $1.1B |
| potentia→HotDoc ↗ | Announced | 2026-02-18 | Not stated in snapshot |
| sigma healthcare→Chemist Warehouse ↗ | Completed | 2026-02-13 | Not stated in snapshot |
| Healthcare Australia→peoplein | Announced | 2025-12-18 | Not stated in snapshot |
A discussion or rumour is not a completed transaction. An unstated value is not zero.
5 postings in the preceding 12 months. The full 25-posting snapshot covers 16 employers.
0 tracked postings mention remote work.
3 postings specify a level.
Top skills across 25 tracked postings in the available jobs snapshot.
| Company | Open roles |
|---|---|
| heidi health ↗ | 8 |
| fatsecret ↗ | 6 |
| 13SICK ↗ | 4 |
| Medtasker ↗ | 3 |
| InMode ↗ | 3 |
| Equalution ↗ | 3 |
| EMvision ↗ | 3 |
| Locum Life ↗ | 3 |
| Company | Employees |
|---|---|
| Global Health ↗ | 10,538 |
| Chemist Warehouse ↗ | 6,565 |
| Eucalyptus ↗ | 472 |
| Seer ↗ | 328 |
| Telix Pharma ↗ | 234 |
| The Better Health Generation ↗ | 207 |
| Alcidion ↗ | 191 |
| Harrison ↗ | 182 |
814 founders and chief executives across 640 companies.
Ex-Princess Alexandra & Wesley Hospitals. The University of Queensland BSc
Ex-Ramsay Health Care, MediRecords, True North Capital · Bond University 2007
Ex-CEO Merck, Director US-ASEAN Business Council, Board Of Directors The Association Of The British Pharmaceutical Industry…
Founder Tissue Repair, Founder Rockhouse Foundation. University of New South Wales BCom 1986.
Blackbird, ex-Fraser's GAMSAT. University of Melbourne MD 2017 & BSc 2013
Speedx, ex-Industry Mentoring Network In Stem, ex-Springboard Enterprises, UNSW, 2007
Ex-Co-Founder-CalorieStory, CalorieKing, Accenture · The University of Western Australia LLB 2001
ex-Medical Device Manufacturers Association, President Boston Scientific. D'Amore-McKim School of Business 1998
The University of Melbourne, Australian-American Fulbright Commission, University of Melbourne…
Medtech Innovator, ex-Australia Post, ex-Ibm, University of Melbourne - Melbourne Business School, 2016
Ex- Liverpool Partners, PLS Management. UNSW BCom 2009
The Digital CEO, McKinsey & Company, TEDxSydney, Ex- CEO Facebook & Instagram, CEBIT Australia. The University of Hong Kong 1986…
70 profiles with education records.
11 profiles with prior-work records.
Profiles cover recorded founders and leaders; contact details remain in Radar.
643,864 articles in the measured 12-month window.
Healthtech coverage across Australia · articles per complete quarter
| Quarter | Articles |
|---|---|
| 2021Q2 | 104,787 |
| 2021Q3 | 121,950 |
| 2021Q4 | 105,334 |
| 2022Q1 | 119,955 |
| 2022Q2 | 112,956 |
| 2022Q3 | 120,774 |
| 2022Q4 | 178,041 |
| 2023Q1 | 201,541 |
| 2023Q2 | 129,399 |
| 2023Q3 | 151,945 |
| 2023Q4 | 137,979 |
| 2024Q1 | 131,947 |
| 2024Q2 | 143,938 |
| 2024Q3 | 143,993 |
| 2024Q4 | 157,185 |
| 2025Q1 | 186,415 |
| 2025Q2 | 119,036 |
| 2025Q3 | 223,500 |
| 2025Q4 | 107,306 |
| 2026Q1 | 123,295 |
Article volume measures coverage, not market sales.
489 recorded company events across 79 companies; percentages use that event total.
Healthtech coverage across Australia · ranked by full-period article count.
Recent and prior counts use the source comparison windows.
Healthtech coverage across Australia
| Keyword | Recent | Prior | Change |
|---|---|---|---|
| countries | 4,005 | 1,939 | 107% |
| domestic robots | 3,109 | 43 | 7130% |
| toy robots | 3,082 | 29 | 10528% |
| ashes moments | 1,191 | 772 | 54% |
| angel investors | 1,017 | 370 | 175% |
| overseas study | 971 | 685 | 42% |
| ashes urn | 897 | 392 | 129% |
| ashes records | 857 | 403 | 113% |
| semester abroad | 817 | 522 | 57% |
| ashes venues | 809 | 429 | 89% |
| test cricket | 5,971 | 11,546 | -48% |
| test innings | 4,543 | 8,864 | -49% |
| 5-day cricket | 3,717 | 7,764 | -52% |
| odi cricket | 2,923 | 6,168 | -53% |
| limited overs cricket | 2,793 | 6,143 | -55% |
Healthtech coverage across Australia
territories, disputed islands, test cricket
27.4% critical · 18.9% positivetest cricket, test innings, odi world cup
31.7% critical · 42.2% positivecore inflation rate, inflation outlook, aflw premiership
31.6% critical · 46.7% positiveHealthtech coverage across Australia. Topic labels describe recorded classifications and can include broad context.
53,214 papers in the recorded worldwide scope.
Tone counts: 46,301 positive · 2,052 neutral · 4,861 negative.
Landmark: Implementation strategies: recommendations for specifying and reporting
Landmark: Deep Learning for Health Informatics
Landmark: Fostering implementation of health services research findings into practice: a consolidated framework for advancing implementation science
Common problems researchers identify · 0119.0% of this theme group
Examines challenges and strategies for building resilient health care systems and administrations.
Health informatics (400) · Health administration (281) · Nursing research (250) · Public health (273)
Resilient Health Care: a systematic review of conceptualisations, study methods and factors that develop resilience
Health systems resilience in practice: a scoping review to identify strategies for building resilience
| Year | Share index |
|---|---|
| 2022 | 23.2 |
| 2023 | 21.1 |
| 2024 | 27.6 |
| 2025 | 44.8 |
Common problems researchers identify · 0218.9% of this theme group
Highlights difficulties in discovering and repurposing drugs for multifactorial diseases.
Drug discovery (321) · Drug (197) · Drug development (103) · Disease (155)
A perspective on multi‐target drug discovery and design for complex diseases
Drug repurposing in oncology: Compounds, pathways, phenotypes and computational approaches for colorectal cancer
| Year | Share index |
|---|---|
| 2022 | 157.3 |
| 2023 | 161.8 |
| 2024 | 169.7 |
| 2025 | 211.5 |
Common problems researchers identify · 0315.9% of this theme group
Discusses barriers to adopting digital health tools and achieving universal coverage.
Digital health (627) · Health care (357) · Digital transformation (69) · eHealth (97)
Technology and Universal Health Coverage: Examining the role of digital health
Engagement With and Acceptability of Digital Media Platforms for Use in Improving Health Behaviors Among Vulnerable Families: Systematic Rev
| Year | Share index |
|---|---|
| 2022 | 538.7 |
| 2023 | 553.0 |
| 2024 | 540.4 |
| 2025 | 843.9 |
Common problems researchers identify · 0414.7% of this theme group
Analyzes practical and regulatory obstacles to scaling telemedicine and telerehabilitation.
Telemedicine (604) · Telehealth (394) · Health care (334) · Telerehabilitation (53)
Opportunities and challenges for telehealth within, and beyond, a pandemic
Strategies for Evaluating Telehealth
| Year | Share index |
|---|---|
| 2022 | 542.2 |
| 2023 | 554.7 |
| 2024 | 541.1 |
| 2025 | 844.0 |
Common problems researchers identify · 0511.7% of this theme group
Focuses on limits of personalized cancer diagnostics, biomarkers, and treatment resistance.
Precision medicine (480) · Personalized medicine (238) · Disease (116) · Precision oncology (28)
Personalized Cancer Medicine: Molecular Diagnostics, Predictive biomarkers, and Drug Resistance
Personalizing Oncology: Perspectives and Prospects
| Year | Share index |
|---|---|
| 2022 | 1255.2 |
| 2023 | 1115.6 |
| 2024 | 1012.0 |
| 2025 | 1296.9 |
Common problems researchers identify · 0610.9% of this theme group
Addresses safety, risk analysis, and regulatory gaps for emerging medical equipment and wearables.
Medical device (221) · Wearable computer (50) · Medical equipment (27) · Risk analysis (34)
Energy sources and their development for application in medical devices
Medical Devices and Health — Creating a New Regulatory Framework for Moderate-Risk Devices
| Year | Share index |
|---|---|
| 2022 | 40.4 |
| 2023 | 42.2 |
| 2024 | 43.7 |
| 2025 | 72.1 |
Common problems researchers identify · 078.8% of this theme group
Explores how COVID‑19 amplified telehealth usage and exposed system weaknesses.
Pandemic (394) · Coronavirus disease 2019 (274) · 2019-20 coronavirus outbreak (69) · Telemedicine (258)
Quantifying the Impact of COVID-19 on Telemedicine Utilization: Retrospective Observational Study
Telemedicine Evaluations in Neuro-Ophthalmology During the COVID-19 Pandemic: Patient and Physician Surveys
| Year | Share index |
|---|---|
| 2022 | 655.3 |
| 2023 | 440.6 |
| 2024 | 327.7 |
| 2025 | 212.1 |
Cautions · 0119.8% of this theme group
Calls for careful evaluation of telehealth effectiveness and patient satisfaction across conditions.
Telemedicine (762) · Telehealth (476) · Telerehabilitation (118) · Health care (319)
The Role of Telemedicine in Improving Healthcare Outcome: A Review
Assessing the Efficiency and Patient Satisfaction of Telemedicine in Managing Chronic Health Conditions
| Year | Share index |
|---|---|
| 2022 | 51.7 |
| 2023 | 48.4 |
| 2024 | 44.2 |
| 2025 | 63.5 |
Cautions · 0219.8% of this theme group
Warns of implementation hurdles for informatics and device solutions in low‑resource settings.
Health informatics (239) · Health administration (157) · Nursing research (113) · Medical device (92)
Challenges of using e-health technologies to support clinical care in rural Africa: a longitudinal mixed methods study exploring primary hea
Development and analysis of quality assessment tools for different types of patient information – websites, decision aids, question prompt l
| Year | Share index |
|---|---|
| 2022 | 23.2 |
| 2023 | 21.1 |
| 2024 | 27.6 |
| 2025 | 44.8 |
Cautions · 0315.3% of this theme group
Notes the need for robust biomarkers and predictive models before clinical adoption.
Drug discovery (202) · Drug (160) · Pharmacogenomics (109) · Pharmacogenetics (64)
Biomarkers: Opportunities and Challenges for Drug Development in the Current Regulatory Landscape
Can We Predict Clinical Pharmacokinetics of Highly Lipophilic Compounds by Integration of Machine Learning or In Vitro Data into Physiologic
| Year | Share index |
|---|---|
| 2022 | 154.6 |
| 2023 | 158.9 |
| 2024 | 165.9 |
| 2025 | 206.7 |
Cautions · 0414.7% of this theme group
Highlights gaps in evidence, usability, and equity for digital psychological interventions.
Digital health (480) · Psychological intervention (265) · Mental health (159) · Health care (262)
Digital Health Interventions to Enhance Prevention in Primary Care: Scoping Review
Digital Health Interventions for Promoting Healthy Aging: A Systematic Review of Adoption Patterns, Efficacy, and User Experience
| Year | Share index |
|---|---|
| 2022 | 790.2 |
| 2023 | 807.5 |
| 2024 | 810.9 |
| 2025 | 1159.7 |
Cautions · 0511.2% of this theme group
Examines clinician concerns and uneven uptake of remote care during the pandemic.
Pandemic (431) · Coronavirus disease 2019 (360) · Telemedicine (348) · 2019-20 coronavirus outbreak (77)
Community Mental Health Clinicians’ Perspectives on Telehealth During the COVID-19 Pandemic: Mixed Methods Study
Exploring Ophthalmologists’ Adoption of Telemedicine during the COVID-19 Pandemic: A Mixed Methods Study
| Year | Share index |
|---|---|
| 2022 | 544.1 |
| 2023 | 376.7 |
| 2024 | 243.3 |
| 2025 | 191.2 |
Cautions · 0610.3% of this theme group
Discusses limited awareness, infrastructure, and ethical issues in personalized oncology.
Precision medicine (249) · Personalized medicine (164) · Cancer (103) · Oncology (57)
Awareness, Understanding, and Adoption of Precision Medicine to Deliver Personalized Treatment for Patients With Cancer: A Multinational Sur
Role of Proteins in Oncology: Advances in Cancer Diagnosis, Prognosis, and Targeted Therapy—A Narrative Review
| Year | Share index |
|---|---|
| 2022 | 767.8 |
| 2023 | 1043.6 |
| 2024 | 798.0 |
| 2025 | 771.4 |
Cautions · 078.8% of this theme group
Raises ethical and reliability questions surrounding artificial‑intelligence tools for precision care.
Applications of artificial intelligence (102) · Transformative learning (77) · Health care (188) · Precision medicine (102)
Artificial intelligence in healthcare: revolutionizing precision medicine, predictive analytics, and ethical considerations in autonomous di
Artificial Intelligence in Medicine: Transforming Diagnosis, Treatment, and Healthcare Delivery
| Year | Share index |
|---|---|
| 2022 | 534.7 |
| 2023 | 549.6 |
| 2024 | 538.1 |
| 2025 | 839.2 |
Opportunities · 0118.0% of this theme group
Identifies design and integration pathways to improve clinical adoption of digital tools.
Digital health (282) · Health care (348) · Health informatics (142) · Psychological intervention (156)
Development of an Evidence-Based Conceptual Model of the Health Care Sector Under Digital Transformation: Integrative Review
HCI-modelling for improving the clinical usability of digital health technologies
| Year | Share index |
|---|---|
| 2022 | 541.3 |
| 2023 | 554.6 |
| 2024 | 543.2 |
| 2025 | 853.3 |
Opportunities · 0216.6% of this theme group
Shows promise for computational docking and virtual screening to accelerate therapeutic discovery.
Drug discovery (282) · In silico (99) · Drug (156) · Docking (85)
Exploring Cimetidine\nas a Potential Therapeutic Attenuator\nagainst Amyloid Formation in Parkinson’s Disease: Spectroscopic\nand Microscopi
Design, Synthesis,\nand Biological Evaluation of 5‑Formyl-pyrrolo[3,2‑<i>b</i>]pyridine-3-carboxamides as New Selective, Potent,
| Year | Share index |
|---|---|
| 2022 | 167.5 |
| 2023 | 172.4 |
| 2024 | 180.4 |
| 2025 | 218.9 |
Opportunities · 0313.8% of this theme group
Highlights advances in modeling chemical space to guide targeted drug design.
Drug discovery (535) · Computational biology (222) · Drug (223) · Chemical space (66)
Assessing molecular docking tools: understanding drug discovery and design
Molecular Docking in Computer-Aided Drug Discovery: A Powerful Tool for Targeted Therapeutics
| Year | Share index |
|---|---|
| 2022 | 281.3 |
| 2023 | 298.1 |
| 2024 | 330.7 |
| 2025 | 367.6 |
Opportunities · 0413.7% of this theme group
Explores new remote therapy models for physical and palliative care delivery.
Telemedicine (475) · Telehealth (353) · Telerehabilitation (87) · Physical therapy (75)
Urgent and non-emergent telehealth care for seniors: Findings from a multi-site impact study
Telehealth for the study of palliative care communication: opportunities, methodological challenges, and recommendations
| Year | Share index |
|---|---|
| 2022 | 51.7 |
| 2023 | 48.4 |
| 2024 | 44.2 |
| 2025 | 63.5 |
Opportunities · 0512.7% of this theme group
Advances methods for tailoring treatments based on individual genetic profiles.
Precision medicine (283) · Personalized medicine (216) · Disease (142) · Pharmacogenomics (61)
Pathways to personalized medicine—Embracing heterogeneity for progress in clinical therapeutics research in Alzheimer's disease
Deep Learning for Precision Medicine: Advancing Personalized Treatment Plans in Oncology
| Year | Share index |
|---|---|
| 2022 | 1255.2 |
| 2023 | 1115.6 |
| 2024 | 1012.0 |
| 2025 | 1296.9 |
Opportunities · 0612.7% of this theme group
Promotes connected devices for continuous patient monitoring and remote health management.
Wearable computer (117) · Medical device (84) · Remote patient monitoring (76) · Internet of Things (49)
Wearable technology. Health-care solutions for a growing global population.
IoT Based Effective Wearable Healthcare Monitoring System For Remote Areas
| Year | Share index |
|---|---|
| 2022 | 40.5 |
| 2023 | 42.2 |
| 2024 | 44.3 |
| 2025 | 74.3 |
Opportunities · 0712.5% of this theme group
Focuses on bioinformatic approaches to identify circulating markers for tailored oncology care.
Cancer (241) · Precision medicine (207) · Breast cancer (90) · Lung cancer (44)
Bioinformatics-Based Analysis of Circulating Tumor Cells: A Methodological Overview of Personalized Cancer Treatment
[Molecular biomarkers in breast cancer : advances in precision medicine].
| Year | Share index |
|---|---|
| 2022 | 776.6 |
| 2023 | 1055.1 |
| 2024 | 810.2 |
| 2025 | 787.3 |
Orientation shares compared with 25,000 papers in the reference sample.
| Research orientation | This field | Reference sample |
|---|---|---|
| Promising | 29.7% | 37.3% |
| Problem-identifying | 29.0% | 9.6% |
| Descriptive | 18.8% | 17.6% |
| Breakthrough | 12.7% | 26.1% |
| Cautionary | 6.4% | 4.5% |
| Comparative | 2.5% | 3.9% |
| Critical | 0.9% | 1.0% |
Counts and shares refer to the stated research pool. A low count describes how much of that research is recorded here, not the absence of a real-world concern.
| Concern / example paper | Papers | Share | Raised as a problem | Worldwide share |
|---|---|---|---|---|
| Privacy & surveillanceThe future of digital health with federated learning | 4,573 | 2.66% | 2,251 (49.2%) | 2.66% |
| Safety & misuseImpact of Rumors and Misinformation on COVID-19 in Social Media | 292 | 0.17% | 167 (57.2%) | 0.17% |
| Bias & fairnessChallenges and recommendations for wearable devices in digital health: Data quality, interoperability, health equity, fa | 99 | 0.06% | 45 (45.5%) | 0.06% |
| Hardware, e-waste & supply chainE-waste for health: recycling smartphones for health monitoring | 24 | 0.01% | 7 (29.2%) | 0.01% |
| Concentration of compute powerDemonopolizing Medical Knowledge | 16 | 0.01% | 7 (43.8%) | 0.01% |
| Labour & data workNew Work—New Interventions: Digital Occupational Health Interventions and the Co-Creation of a Human-Centered Future of | 11 | 0.01% | 6 (54.5%) | 0.01% |
| Energy & datacenter footprintSUSTAINABLE GREEN COMPUTING FOR MEDICAL APPLICATIONS: ADVANCING RESPONSIBLE HEALTHCARE IT | 10 | 0.01% | 4 (40.0%) | 0.01% |
| Carbon & emissions of computeSustainable AI-Enabled UAV Healthcare Logistics: Environmental, Social, and Governance Implications from a PRISMA-ScR Re | 3 | 0.0% | 1 (33.3%) | 0.0% |
| Water use | 0 | 0.0% | 0 (%) | 0.0% |
Institution and researcher rankings use citations to their covered work. Research scope: worldwide. This may be broader than the company geography.
Published patent filings in the recorded source window.
Compare demand signals in Australia’s newsflow with the healthtech categories mapped to each signal.
Signal percentile − supply percentile = gap in percentile points. Positive gaps highlight questions to investigate. A high signal can reflect spending pressure or access friction, as well as potential demand.
The comparison is relative to the signal families on this page. A supply percentile of zero means the lowest relative reading, not zero companies. It is a prioritisation clue, not measured market size or unmet demand.
Signal and mapped-supply percentiles, their gap, and change in the signal’s article share.
Swipe horizontally to compare all columns →
| Signal family | Signal percentile | Supply percentile | Relative gap | Gap (points) | Signal share vs prior year |
|---|---|---|---|---|---|
| Mental health ↗Disease Burden | 62.5 | 50.0 | +12.5 | +26.6% | |
| Ageing & elder care ↗Disease Burden | 0.0 | 0.0 | +0.0 | +2.2% | |
| Cancer burden ↗Disease Burden | 37.5 | 100.0 | -62.5 | +38.0% | |
| Maternal & child health ↗Disease Burden | 62.5 | — | No matching category | — | +62.8% |
| Layoffs & income shocks ↗Spending Pressure | 87.5 | — | No matching category | — | +94.9% |
Showing all 5 signals. Select a family for its history and mapped categories.
All 8 city readings for these demand families in the comparison geography. Australia is highlighted.
Each city’s reading is a share of its own coverage.
Maternal & child health · Mental health · Ageing & elder care
Maternal & child health · Ageing & elder care · Mental health
Mental health · Layoffs & income shocks · Maternal & child health
Mental health · Maternal & child health · Ageing & elder care
Maternal & child health · Cancer burden · Mental health
Mental health · Layoffs & income shocks · Maternal & child health
Cancer burden · Mental health · Maternal & child health
Mental health · Layoffs & income shocks · Maternal & child health
Mental-health pressure can pull counselling and tele-psychiatry demand where it surfaces.
Companies can appear in multiple categories; these counts are not a unique-company total.
Mentions per 10,000 articles · zero baseline
| Quarter | Mentions | Per 10,000 articles |
|---|---|---|
| 2024Q3 | 126 | 18.69 |
| 2024Q4 | 282 | 35.85 |
| 2025Q1 | 87 | 11.01 |
| 2025Q2 | 94 | 16.1 |
| 2025Q3 | 142 | 17.26 |
| 2025Q4 | 294 | 51.15 |
| 2026Q1 | 129 | 21.25 |
An ageing base can shift demand toward geriatric, home and chronic care.
Companies can appear in multiple categories; these counts are not a unique-company total.
Mentions per 10,000 articles · zero baseline
| Quarter | Mentions | Per 10,000 articles |
|---|---|---|
| 2024Q3 | 82 | 12.16 |
| 2024Q4 | 137 | 17.42 |
| 2025Q1 | 79 | 10.0 |
| 2025Q2 | 91 | 15.59 |
| 2025Q3 | 112 | 13.62 |
| 2025Q4 | 61 | 10.61 |
| 2026Q1 | 60 | 9.89 |
Cancer burden can pull screening, diagnostics and oncology capacity demand.
Companies can appear in multiple categories; these counts are not a unique-company total.
Mentions per 10,000 articles · zero baseline
| Quarter | Mentions | Per 10,000 articles |
|---|---|---|
| 2024Q3 | 73 | 10.83 |
| 2024Q4 | 86 | 10.93 |
| 2025Q1 | 75 | 9.49 |
| 2025Q2 | 63 | 10.79 |
| 2025Q3 | 129 | 15.68 |
| 2025Q4 | 73 | 12.7 |
| 2026Q1 | 72 | 11.86 |
Maternal and child burden can pull immunisation, nutrition and pediatric care demand.
This signal has no matching category in the page’s healthtech market map, so no supply percentile or gap is assigned.
Mentions per 10,000 articles · zero baseline
| Quarter | Mentions | Per 10,000 articles |
|---|---|---|
| 2024Q3 | 85 | 12.61 |
| 2024Q4 | 70 | 8.9 |
| 2025Q1 | 89 | 11.27 |
| 2025Q2 | 86 | 14.73 |
| 2025Q3 | 168 | 20.42 |
| 2025Q4 | 71 | 12.35 |
| 2026Q1 | 63 | 10.38 |
Layoff cycles can pull discretionary spend back toward value offerings.
This signal has no matching category in the page’s healthtech market map, so no supply percentile or gap is assigned.
Mentions per 10,000 articles · zero baseline
| Quarter | Mentions | Per 10,000 articles |
|---|---|---|
| 2024Q3 | 88 | 13.05 |
| 2024Q4 | 101 | 12.84 |
| 2025Q1 | 96 | 12.15 |
| 2025Q2 | 61 | 10.45 |
| 2025Q3 | 215 | 26.14 |
| 2025Q4 | 105 | 18.27 |
| 2026Q1 | 154 | 25.37 |
Australia healthtech coverage
Australian & New Zealand Journal of Psychiatry
557 citations in the snapshot
Clinical Infectious Diseases
472 citations in the snapshot
The Medical Journal of Australia
439 citations in the snapshot
Scientific Reports
389 citations in the snapshot
Australia coverage of this page's demand families
| Keyword | Recent articles | Prior articles | Share change |
|---|---|---|---|
| school-entry vaccine requirements | 82 | 29 | 224.9% |
| elderly vaccination guidelines | 83 | 35 | 172.5% |
| childhood immunization laws | 84 | 36 | 168.1% |
| healthy diet cancer | 53 | 24 | 153.7% |
| pediatric catch-up vaccinations | 93 | 52 | 105.5% |
| online safety parenting | 73 | 129 | -35.0% |
Share changes describe coverage in the stated comparison periods, not search demand or market size.
Company counts, hiring and disclosed funding across the recorded hubs.
33.5% across the displayed hubs
13 companies hiring · $799.4M disclosed funding
Explore companies in Sydney ↗
32.7% across the displayed hubs
14 companies hiring · $618.7M disclosed funding
Explore companies in Melbourne ↗
15.3% across the displayed hubs
8 companies hiring · $523.2M disclosed funding
Explore companies in Brisbane ↗
7.7% across the displayed hubs
9 companies hiring · $202.6M disclosed funding
Explore companies in Perth ↗
6.1% across the displayed hubs
0 companies hiring · $169.6M disclosed funding
Explore companies in Adelaide ↗1.7% across the displayed hubs
0 companies hiring · $0 disclosed funding
Explore companies in Gold Coast ↗1.6% across the displayed hubs
2 companies hiring · $33.2M disclosed funding
Explore companies in Surry Hills ↗
1.5% across the displayed hubs
0 companies hiring · $500.0K disclosed funding
Explore companies in Canberra ↗Clear definitions for making better comparisons.
It measures the tracked company ecosystem, recorded funding, hiring and other available evidence. It is not a market-size estimate.
No. A company can belong to several segments, so segment counts and funding can overlap.
A dash or unavailable panel means the current reviewed source snapshot does not support that figure.
Company ecosystem snapshot: 31 August 2026. Funding is recorded in USD; filed accounts retain their stated currency and reporting basis. Each section identifies its own coverage. The news and research behind these sections is explorable in Prism.
Canonical landscape ↗